Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693830 · ClinicalTrials.gov registry record · NA
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
A NA study of Lymphoma and Diffuse Large B Cell Lymphoma, sponsored by Hua-Jay J Cherng, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06693830: Recruiting NA study of Lymphoma and Diffuse Large B Cell Lymphoma, sponsored by Hua-Jay J Cherng, MD.
NCT06693830 is a NA study of Lymphoma and Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Hua-Jay J Cherng, MD. The registered enrollment target is 40 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693830, a NA study of Lymphoma and Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Hua-Jay J Cherng, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatment who receive a shortened course of chemotherapy. There are no investigational drug agents to be administered in this study. The investigational assay, phased variant enrichment and detection sequencing (PhasED-seq) will be used to guide de-escalation of standard-of-care therapy for newly diagnosed DLBCL. The PhasED-seq assay has not yet been approved by the Food and Drug Administration (FDA).
Primary Outcome
Success defined as: C4D1 sample collected, DNA successfully sequenced from the diagnostic tissue sample, C4D1 timepoint result must be available within 28 days of C4D1
Conditions Studied
Interventions
- OTHER Standard of Care Treatment
- DEVICE Phased Variant Enrichment and Detection Sequencing (PhasED-seq)
- OTHER De-escalated Treatment
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2029-12 |
| Phase | NA |
What NCT06693830 shows while recruiting
NCT06693830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower).
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care Treatment is the first listed.
NCT06693830 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06693830 about?
NCT06693830 is a clinical study titled "ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL". The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatme...
What is the current status of trial NCT06693830?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-12-11. Estimated completion is 2029-12.
What conditions does trial NCT06693830 study?
This clinical trial studies the following conditions: Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, High Grade B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.
What interventions are being tested in trial NCT06693830?
The interventions under investigation include: Standard of Care Treatment (OTHER), Phased Variant Enrichment and Detection Sequencing (PhasED-seq) (DEVICE), De-escalated Treatment (OTHER).
Who is sponsoring clinical trial NCT06693830?
This trial is sponsored by Hua-Jay J Cherng, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693830 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06693830's enrollment target sits among peer trials
40 174th of 299 higher than 116 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
- NCT02254863 · 40 participants · Phase 1
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI